News
CCRM Fertility acquires The Institute for Reproductive Medicine & Science
The American company specialises in fertility treatments, IVF, fertility testing and fertility preservation
The US fertility provider, CCRM Fertility, has announced the acquisition of The Institute for Reproductive Medicine & Science (IRMS).
With the new addition of IRMS, the fertility company will now serve 11 major metropolitan areas with 34 locations across the US and Canada.
Jon Pardew, president and CEO of CCRM Fertility, said the acquisition is just one piece to the company’s overall growth strategy, further strengthening its commitment to its patients, physicians, technologies, fertility care and research.
“Bringing IRMS into our family made perfect sense,” he added. “It has a longstanding reputation for world-class services, personalised fertility treatment and access to care through convenient locations.
“We are confident IRMS’s diverse and experienced team of physicians and embryologists will be an excellent addition to the CCRM Fertility team. Our combined commitment to quality care and innovative solutions now makes us one of the largest and most advanced network of fertility clinics servicing North America.”
The IRMS clinical director, Dr Debbra Keegan, said: “The IRMS team is incredibly excited to join the CCRM Fertility network as we expand our philosophy of care throughout the State of New Jersey and beyond.
“We chose CCRM Fertility because of our common commitment to patient-centric care, best practices in medicine and scientific expertise. We look forward to this partnership bringing yet another level of superior reproductive care to our valuable patients.”
CCRM Fertility specialises in fertility treatments, IVF, fertility testing, fertility preservation, genetic testing, third-party reproduction and egg donation.
The addition of IRMS will combine the two companies’ scientific advances, laboratory techniques and full suite of reproductive services.
The acquisition comes weeks after the fertility provider announced the expansion of its partnership with TMRW Life Sciences, the world’s first automated platform for the management and care of the frozen eggs and embryos used in IVF.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Pregnancy
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Fertility2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Wellness3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






